Zofran MDL Plaintiffs Say ‘Clear Evidence’ Preemption Motion Is Premature

(January 20, 2016, 11:49 AM EST) -- BOSTON — Plaintiffs in the Zofran birth defect multidistrict litigation on Jan. 5 opposed defendant GlaxoSmithKline LLC’s (GSK) motion to dismiss the entire litigation, saying that if there is any “clear...
To view the full article, register now.